


Aryl-Pyridine Derivatives

The present invention is concerned with novel pyrimidine derivatives useful as 11b-HSD1 inhibitors (T2D).

The invention is concerned particularly with compounds of formula I



(I)

and pharmaceutically acceptable salts and esters thereof, wherein

R¹ is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;

R² is hydrogen, alkyl or halogen;

10 R³ is hydrogen, alkyl or halogen;

R⁴ is phenyl, naphthyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO₂- ;

- 2 -

R⁵ is hydrogen or alkyl;

R⁶, R⁷, R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, alkyl, halogen, cyano, trifluoromethyl, alkoxy and alkyl-SO₂-;

A is nitrogen or C-R¹⁰;

5 E is nitrogen or C-R⁹;

G is nitrogen or C-R⁸; and

wherein not more than one of A, E and G is nitrogen.

Glucocorticoids (cortisol in humans, corticosterone in mice and rats) are an important class of adrenocorticosteroids that regulate many metabolic and homeostatic processes and form a key component of the response to stress. Glucocorticoids act via intracellular glucocorticoid receptors and, in some tissues, mineralocorticoid receptors; both being nuclear transcription factors. Glucocorticoid action on target tissues depends not only on circulating steroid concentrations and the cellular expression of receptors, but also on intracellular enzymes that critically determine to which extent glucocorticoids gain access to receptors in an active forms. 11beta-hydroxysteroid dehydrogenases (11beta-HSD's) catalyze the interconversion of the principal active 11-hydroxy-glucocorticoid (Cortisol in men) and their inactive 11-keto metabolites (cortisone in men).

The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) interconverts inactive into active glucocorticoids, thereby playing a major role in local modulation of cellular agonist concentration and thus activation of corticosteroid receptors in target tissues. In a recent study made by F. Hoffmann-La Roche differences in gene expression in lean and obese men were analyzed using gene array technology in order to identify specific changes in gene expression that might be associated with insulin resistance or altered metabolism. This study revealed that the mRNA for 11beta-HSD1 is approximately two-fold up regulated in adipose tissue in obese individuals. Moreover, overexpressing 11beta-HSD1 in adipocytes of mice led to visceral obesity and to a syndrome-X like phenotype (Masuzaki H. et al., Science. 2001 Dec 7; 294(5549):2166-70.). Taken together, these data very strongly support an important role of 11beta-HSD1 in the induction of obesity and the impairment of glucose homeostasis and lipid parameters. Thus, selective inhibition of this enzyme could lower blood glucose levels in Type 2

diabetic patients, normalize elevated lipid parameters and/or reduce weight in obese subjects .

The first pharmacological indication that 11beta-HSD1 inhibition in men might have beneficial effects were obtained by using carbenoxolone, an anti-ulcer drug which
5 inhibits both 11beta-HSD1 and the related enzyme 11beta-HSD2. Treatment with carbenoxolone led to an increase in insulin sensitivity indicating that that inhibition of 11beta-HSD1 may reduce cellular cortisol levels and therefore minimizing some of its deleterious effects. (Walker et al. 1995; J. Clin. Endocrinol. Metab. 80, 31155-3159).


11beta-HSD1 is expressed in many tissues including liver, adipose tissue, vascular
10 smooth muscles, pancreas and brain. Its activity is dependent on NADP(H) and it has a relatively low affinity for its substrate (compared to 11beta-HSD2). 11 beta-HSD1 in tissue homogenates and when purified is bidirectional, exhibiting both 11beta-dehydrogenase and 11beta-reductase reactions, with greater stability of the dehydrogenase activity (P.M. Stewart and Z.S. Krozowski, Vitam. Horm. 57 (1999), pp. 249-324). However, when the
15 enzyme activity is tested in intact cells, the 11beta-reductase activity predominates, which regenerates active glucocorticoids from inert 11-keto forms. Such glucocorticoid regeneration will increase effective intracellular glucocorticoid levels and thereby amplifying glucocorticoid activity. It is this elevated cellular cortisol concentration that might lead to increased hepatic glucose production, adipocyte differentiation and insulin
20 resistance.

Inhibition of 11beta-HSD1 should not only reduce the typical Syndrome-X / Diabetes associated symptoms, but it should also be save and without major side effect. Studies with the unspecific inhibitor carbenoxolone highlight the importance of developing specific 11beta-HSD1 inhibitors. The inhibition of the 11beta-HSD2 enzyme is
25 badly tolerated and results in increased blood pressure. In contrast inhibition of 11beta-HSD1 should be well tolerated since 11beta-HSD1 knockout mice were found be healthy and to resist hyperglycemia provoked by obesity or stress (Kotelevtsev Y. et al., Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14924-9). Similar upon starvation these mice had attenuated activation of key hepatic enzymes that are involved in gluconeogenesis. In
30 addition, these mice had improved lipid and lipoprotein profiles suggesting that inhibition of HSD1 might be highly efficacious and safe. Recent reports indicate that 11beta-HSD1 inhibitors might also be beneficial to reduce high blood pressure (Masuzaki H. et al., J Clin Invest. 2003 July;112(1):83-90; Rauz S. et al., QJM. 2003 July;96(7):481-90) to improve

cognition (Sandeep TC. et al., Proc Natl Acad Sci U S A. 2004 Apr. 27;101(17):6734-9) or to improve Alzheimer associated deficits. Taken together 11beta-HSD1 inhibition might be a save and efficacious approach to treat symptoms of diabetes, obesity and other diseases.

The compounds of formula I and their pharmaceutically acceptable salts and esters are novel and have valuable pharmacological properties. In particular they are 11b-HSD1 inhibitors (T2D) and they display selectivity against the related 11beta-HSD2 enzyme. Therefore the compounds which are specific 11beta-HSD1 inhibitors (T2D) represent an approach to e.g. lower blood glucose levels and normalize lipid parameters in Type 2 diabetic patients by modulating the local concentration of the active glucocorticoid Cortisol in target tissue (liver, adipose tissue).

In a first aspect, there is provided compounds of formula



wherein

R¹ is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;

R² is hydrogen, alkyl or halogen;

R³ is hydrogen, alkyl or halogen;

R⁴ is phenyl, naphthyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl,

alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxyalkylalkoxy and alkyl-SO₂-;

R⁵ is hydrogen or alkyl;

R⁶, R⁷, R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, alkyl, halogen, cyano, trifluoromethyl, alkoxy and alkyl-SO₂-;

A is nitrogen or C-R¹⁰;


E is nitrogen or C-R⁹;

G is nitrogen or C-R⁸;


wherein not more than one of A, E and G is nitrogen;

and pharmaceutically acceptable salts and esters thereof.

In a second aspect, there is provided a process for the preparation of a compound as defined above comprising the reaction of a compound according to formula



in the presence of a compound according to formula



wherein R¹ to R⁷, A, E and G are defined as in claim 1.

In a third aspect, there is provided compounds as defined above for use as therapeutically active substance.

In a fourth aspect, there is provided compounds as defined above for the preparation of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the enzyme 11beta-hydroxysteroid dehydrogenase1.

In a fifth aspect, there is provided a pharmaceutical composition comprising a compound as defined above and a therapeutically inert carrier.

In a sixth aspect, there is provided the use of a compound as defined above for the preparation of medicaments for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension.

In a seventh aspect, there is provided the use of a compound as defined above for the preparation of medicaments for the treatment and prophylaxis of diabetes Type II.

In an eighth aspect, there is provided a compound as defined above, when manufactured according to the second aspect.

The disclosed compounds can be used in the prophylaxis and/or treatment of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II.

The disclosed compounds can further be used in the prophylaxis and/or treatment of high ocular eye pressure, cognition, Alzheimer and/or neurodegeneration.

Disclosed herein are the compounds of formula I and their aforementioned salts and esters per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts and esters, the use of the said compounds, esters and salts for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of eating disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II, and the use of the said compounds, salts and esters for the production of medicaments for the treatment or prophylaxis of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II.

The disclosed compounds can further be combined with PPAR (alpha, gamma, delta) agonists, DHEA (dehydroepiandrosterone), DPPIV inhibitors, insulin and/or lipase inhibitors, particularly orlistat.

In the present description the term "alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly preferred

a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched C₁-C₈ alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, preferably methyl and ethyl and most preferred methyl.

5 The term "cycloalkyl", alone or in combination, signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms. Examples of C₃-C₈ cycloalkyl are cyclopropyl, methyl-cyclopropyl, dimethylcyclopropyl, cyclobutyl, methyl-cyclobutyl, cyclopentyl, methyl-cyclopentyl, cyclohexyl, methyl-cyclohexyl, dimethyl-cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl.

10 The term "alkoxy", alone or in combination, signifies a group of the formula alkyl-O- in which the term "alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tert.butoxy, preferably methoxy and ethoxy and most preferred methoxy.

15 The term "hydroxyalkyl", alone or in combination, signifies an alkyl group as defined before, wherein one or more hydrogen atoms, preferably one hydrogen atom is replaced by a hydroxy group. Examples of hydroxyalkyl are hydroxymethyl and hydroxyethyl.

20 The term "aryl", alone or in combination, signifies a phenyl or naphthyl group, preferably a phenyl group which optionally carries one or more substituents, preferably one to three, each independently selected from halogen, trifluoromethyl, trifluoromethoxy, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylenedioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl, dialkylaminocarbonyl, hydroxy, nitro, alkyl-SO₂-, amino-SO₂-, cycloalkyl and the like. Preferred is phenyl or naphthyl, particularly phenyl optionally substituted with one to three, preferably one or
25 two substituents independently selected from alkyl, halogen, alkoxy, trifluoromethoxy, nitro and trifluoromethyl. Particularly preferred is phenyl.

 The term "aryloxy", alone or in combination, signifies a aryl-O- group in which the term "aryl" has the previously given significance.

30 The term "heterocyclyl", alone or in combination signifies a saturated, partially unsaturated or aromatic 5- to 10-membered heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur. If desired, it can be substituted

on one or more carbon atoms e.g. by halogen, alkyl, alkoxy, oxo etc. and/or on a secondary nitrogen atom (i.e. -NH-) by alkyl, cycloalkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. =N-) by oxido, with halogen, alkyl, cycloalkyl and alkoxy being preferred. Examples of such heterocyclyl groups are

5 pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrazoyl, imidazolyl (e.g. imidazol-4-yl and 1-benzyloxycarbonyl-imidazol-4-yl), pyrazoyl, pyridyl, pyrazinyl, pyrimidinyl, hexahydro-pyrimidinyl, furyl, thienyl, thiazolyl, oxazolyl, indolyl (e.g. 2-indolyl), quinolyl (e.g. 2-quinolyl, 3-quinolyl and 1-oxido-2-quinolyl), isoquinolyl (e.g. 1-isoquinolyl and 3-isoquinolyl), tetrahydroquinolyl (e.g. 1,2,3,4-tetrahydro-2-quinolyl),

10 1,2,3,4-tetrahydroisoquinolyl (e.g. 1,2,3,4-tetrahydro-1-oxo-isoquinolyl) and quinoxaliny. Preferred examples are thiophenyl, quinolyl, piperidyl, morpholyl, thiomorpholyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl and thiazolyl.

The term "amino", alone or in combination, signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group

15 carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substituents together forming a ring, such as, for example, -NH₂, methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc., preferably primary amino, dimethylamino and diethylamino and particularly

20 dimethylamino.

The term "halogen", alone or in combination, signifies fluorine, chlorine, bromine or iodine and preferably fluorine, chlorine or bromine.

The term "carbonyl", alone or in combination, signifies the -C(O)- group.

The term "oxy", alone or in combination, signifies the -O- group.

25 The term "nitro", alone or in combination signifies the -NO₂ group.

The term "cyano", alone or in combination signifies the group -CN.

The term "pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as

30 hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric

acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. In addition these salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polymine resins and the like. The compound of formula I can also be present in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of compounds of formula I are the hydrochloride salts.

The compounds of formula I can also be solvated, e.g. hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration). The term pharmaceutically acceptable salts also includes physiologically acceptable solvates.

"Pharmaceutically acceptable esters" means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.

The compounds of formula I can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.

Preferred are the compounds of formula I and pharmaceutically acceptable salts thereof, particularly the compounds of formula I.

- 8 -

Further preferred are compounds of formula I, wherein R^1 is hydrogen. Also preferred are compounds of formula I, wherein R^1 is alkyl, preferably methyl.

Another preferred object of the present invention are the compounds of formula I, wherein R^2 is hydrogen. Further preferred are those compounds according to formula I, wherein R^2 is alkyl. Particularly preferred are those compounds of formula I, wherein R^2 is methyl.

Also preferred are the compounds of formula I, wherein R^3 is hydrogen. Further preferred are those compounds according to formula I, wherein R^3 is alkyl.

Another preferred aspect of the present invention are compounds of formula I, wherein R^5 is hydrogen.

Particularly preferred are those compounds of formula I, wherein A is $C-R^{10}$. Further preferred are those compounds of formula I, wherein A is nitrogen.

Preferred are those compounds of formula I, wherein E is $C-R^9$. Further preferred are those compounds of formula I, wherein E is nitrogen.

Another preferred aspect of the present invention are the compounds of formula I, wherein G is $C-R^8$. Also preferred are those compounds of formula I, wherein G is nitrogen.

Preferred are the compounds of formula I, wherein R^4 is phenyl, naphthyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one to three, preferably one or two substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO₂-.

Further preferred are compounds of formula I, wherein R^4 is phenyl optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO₂-.

Particularly preferred are those compounds of formula I, wherein R⁴ is phenyl substituted with one to three substituents independently selected from alkyl, halogen and trifluoromethyl.

Preferred are compounds of formula I, wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ are
5 independently selected from hydrogen, alkyl, halogen and trifluoromethyl.

Particularly preferred are those compounds of formula I, wherein R⁶ is halogen, alkyl or trifluoromethyl. Especially preferred are those compounds of formula I, wherein R⁶ is chloro, methyl or trifluoromethyl.

Examples of preferred compounds of formula (I) are:

- 10 1. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
2. 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
4. 4a) 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-
benzenesulfonamide; 4b) 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-
15 yl]-2-methyl-benzenesulfonamide;
5. Biphenyl-4-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
6. 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-
benzenesulfonamide;
7. 3-Chloro-N-[5-(3-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 20 8. 3-Chloro-N-[5-(2,4-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
9. N-[5-(2,4-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
10. 3-Chloro-N-[5-(4-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
11. 3-Chloro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
12. 5-Fluoro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 25 13. 5-Fluoro-N-[5-(2-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;

- 10 -

14. 3-Chloro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
15. 5-Fluoro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
16. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
17. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
- 5 18. 3-Chloro-N-[5-(4-methanesulfonyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
19. 3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
20. 5-Fluoro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 10 21. 3-Chloro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
22. 5-Fluoro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 15 23. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
24. 3,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
25. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
26. 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
27. 3,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 20 28. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
29. 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
30. 5-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;

31. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
32. 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
33. 4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide;
- 5 34. 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
35. 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
36. Piperidine-1-sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide;
37. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-2-trifluoromethyl-benzenesulfonamide;
- 10 38. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
39. N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
40. N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
41. 3-Chloro-N-[5-(2,5-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
42. 5-Fluoro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-
15 benzenesulfonamide;
43. 3-Chloro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
44. 3-Chloro-2-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 20 45. 3-Chloro-4-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
46. 5-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methoxy-benzenesulfonamide;
47. N-{2-Chloro-4-[5-(2,4-dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenyl}-
25 acetamide;

48. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
49. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-methylsulfonyl-benzenesulfonamide;
50. 3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
51. N-[5-(2,3-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
- 5 52. N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-2-methyl-benzenesulfonamide;
53. N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-methyl-benzenesulfonamide;
54. 3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 10 55. Piperidine-1-sulfonic acid [5-(2,3-dichloro-phenyl)-pyridin-2-yl]-amide;
56. 5-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methoxy-benzenesulfonamide;
57. N-{2-Chloro-4-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylsulfamoyl]-phenyl}-acetamide;
- 15 58. N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
59. N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methanesulfonyl-benzenesulfonamide;
60. {4-[5-(2,3-Dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl
20 ester;
61. N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide;
62. 3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
- 25 63. 4-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;

64. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-(2-hydroxy-ethoxy)-benzenesulfonamide;
65. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
66. 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-
5 benzenesulfonamide;
67. 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
68. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
69. Piperidine-1-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
- 10 70. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
71. 4-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
72. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
73. 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-5-methyl-
15 benzenesulfonamide;
74. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide
75. 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
76. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-
20 benzenesulfonamide;
77. 5-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
78. 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
79. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;

80. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
81. N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 82. N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
83. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
84. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-ethyl-benzenesulfonamide;
85. 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 10 86. 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
87. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-ethyl-benzenesulfonamide;
88. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
89. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 15 90. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide;
91. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
92. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
93. 4-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
- 20 94. 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
95. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
96. 3,5-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;

97. N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
98. N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
99. N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-
5 benzenesulfonamide;
100. 4-Chloro-N-[5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
101. 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 10 102. 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
103. 4-Chloro-N[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
104. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide;
105. 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
106. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 15 107. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-methyl-benzenesulfonamide;
108. N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
109. 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-
20 benzenesulfonamide;
110. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
111. 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 25 112. N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide;

113. N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
114. 2-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide;
- 5 115. 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
116. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
117. 3-Chloro-N-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 10 118. 2-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide;
119. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide;
120. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-fluoro-4-methyl-benzenesulfonamide;
- 15 121. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3,5-dimethyl-benzenesulfonamide;
122. N-[5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
123. 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
124. 3-Chloro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-
20 benzenesulfonamide;
125. N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
126. N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
127. 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-
25 benzenesulfonamide;

128. 3-Chloro-N-[5-(6-chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
129. N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 130. N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
131. N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
132. N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-
10 benzenesulfonamide;
133. 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
134. N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 15 135. N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
136. 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
137. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
138. 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl-
20 benzenesulfonamide;
139. 3-Chloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
140. N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
141. N-[5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 25 142. 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;

143. 3-Chloro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
144. N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 145. N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
146. N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
147. 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 10 148. N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
149. N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
150. 3-Chloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 15 151. 2,4-Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
152. N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
153. 2,4-Dichloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 20 154. N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
155. 2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
156. N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide;
- 25 157. N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-methyl-benzenesulfonamide;
158. N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;

159. N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide;
160. 3-Chloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 5 161. 3-Chloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
162. 4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
163. 4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
164. N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-fluoro-
10 benzenesulfonamide;
165. 2,4-Dichloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
166. N-[5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 15 167. N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
168. 3-Chloro-N-[5-(2-chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-benzenesulfonamide;
169. N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
170. N-(2-Methyl-[3,3']bipyridinyl-6-yl)-3-trifluoromethyl-benzenesulfonamide;
- 20 171. 3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
172. N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
173. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 25 174. 3-Chloro-N-(2-methyl-[3,3']bipyridinyl-6-yl)-benzenesulfonamide;

- 20 -

175. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
176. N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide; and
- 5 177. 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide.

Examples of particularly preferred compounds of formula (I) are:

- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
- 10 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- 15 Piperidine-1-sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-
- 20 benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;

- 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 10 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- 15 N-[5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl-
- 20 benzenesulfonamide;
- 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;

- 22 -

2,4-Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;

2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;

5 N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide;

3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;

N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;

3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;

10 N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide; and

2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide.


15 Processes for the manufacture of compounds of formula I are an object of the invention.

The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following Schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those in the art. The substituents and indices used in
20 the following description of the processes have the significance given above unless indicated to the contrary.

Compounds of general formula I can be obtained according to scheme 1 from compounds of formula II comprising R¹ to R⁷ substituents and A, E, G definitions according to the above description via a condensation reaction with aryl, heteroaryl or
25 heterocyclyl sulfonyl chlorides, in the presence of a base such as triethylamine or (4-dimethylamino)-pyridine (DMAP) in a solvent such THF, ethanol, methylene chloride DMF or DMSO, or in pyridine as a solvent, with or without the addition of a base such as triethylamine or DMAP, at room temperature or at elevated temperatures, to give compounds of general formula I. Compounds of formula I where R⁵ equals alkyl can also


be prepared from compounds of formula I where R⁵ equals H via an alkylation reaction, using, for example, NaH as a base and DMF as solvent, at room temperature or at elevated temperatures.

Scheme 1



- 5 Alternatively, compound of general formula I can be prepared according to scheme 2 from compounds of general formula III in a substitution reaction with an corresponding aryl heteroaryl or heterocyclyl sulphonamide, in the presence of a base such as sodium hydride, Na₂CO₃ or triethyl amine and in a solvent such as THF, DMF or DMSO at room temperature or at elevated temperatures. The reaction can also be carried out under the
- 10 condition of an Ullman-type reaction with, for example Cu(I) chloride, or Cu(I) iodide in a solvent such as dioxane or DMF, in analogy to a method described by S.L. Buchwald (J. Am. Chem. Soc., 2001, 7727).


Scheme 2



- A further alternative consists of reacting compounds of general formula IV via a metal-
- 15 catalysed (Pd or Ni) cross-coupling reaction with corresponding organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-,


Stille- or Negishi-type coupling reactions (for literature: Suzuki, Chem. Rev., 1995, 95, 2475; Stille, Angew. Chem. IEE, 1986, 25, 508; Negishi, Acc. Chem. Res., 1982, 15, 340).

Scheme 3



Intermediates II, III and IV are either commercially available, known in the literature or can be prepared by applying a sequence of standard reactions known in the art and outlined in scheme 4. Thus, starting from appropriate 2-pyridones of formula V, which are either known in the literature or can be prepared according to standard procedures, subsequent halogenation with POCl₃, PCl₃ or POBr₃ gives rise to the corresponding 2-chloro or 2-bromo pyridines of formula VI. The iodo derivatives can be obtained from the chloro or bromo derivatives via halogen exchange with NaI (for general reaction of this type: R.C. Corcoran, Tetrahedron Lett. 1990, p6757). Subsequent reaction with alkyl amines or ammonia, either applied in excess, without solvent, or in equimolar amounts, in a suited solvent such as ethanol, water, DMF or THF, gives rise to compounds of formula VII. The reaction can also be performed in an autoclave at elevated pressure in analogy to published procedures (for an example: T. Haga, Heterocycles, 22, p117).

Scheme 4




Compounds of formula II can then be prepared from VII via a metal-catalysed (Pd or Ni) cross-coupling reaction with corresponding organometallic reagent such as (hetero)arylboron, (hetero)arylzinc or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions as described above. The amino group can optionally be protected with standard protecting groups such as BOC or pivaloyl prior to performing the cross-coupling reaction. Compounds of formula III are obtained from compounds of formula VIII (prepared from V via metal-catalysed cross-coupling as for II) by an halogenation reaction (as for the preparation of VI). Compounds of formula IV can be prepared from VI via a nucleophilic substitution reaction with a corresponding aryl, heteroaryl or heterocyclyl sulfonamide in a solvent such as DMSO or DMF in the


- 26 -

presence of a base such as sodium hydride, at room temperature or at elevated temperature. The sulfonamides used in this step are either commercial, known in the literature or can be obtained by standard procedures known in the art. They can also first be converted into their sodium or potassium and these salts can then be used in the
 5 reaction, a procedure which does not require the addition of further base. Alternatively, IV can be obtained from VII by reacting with the corresponding aryl, heteroaryl or heterocyclyl sulfonyl chlorides as described above.

A preferred process for the preparation of a compound of formula I, wherein R¹ to
 10 R⁷, A, E and G are defined as before comprises the reaction of a compound according to formula



in the presence of a compound according to formula



15 wherein R¹ to R⁷, A, E and G are defined as before. Particularly preferred is the above process in the presence of a base such as triethylamine or (4-dimethylamino)-pyridine (DMAP) in a solvent such THF, ethanol, methylene chloride DMF or DMSO, or in pyridine as a solvent, with or without the addition of a base such as triethylamine or DMAP, at room temperature or at elevated temperatures.

20 Preferred intermediates are:

- 5-(2-chloro-phenyl)-pyridin-2-ylamine;
- 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine;
- 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine;

- 5-(2-chloro-4-fluoro-phenyl)-pyridin-2-ylamine;
5-(3-fluoro-phenyl)-pyridin-2-ylamine;
5-(2,4-difluoro-phenyl)-pyridin-2-ylamine;
5-(4-methoxy-phenyl)-pyridin-2-ylamine;
5 5-(4-fluoro-phenyl)-pyridin-2-ylamine;
5-(2-methoxy-phenyl)-pyridin-2-ylamine;
5-(2-fluoro-phenyl)-pyridin-2-ylamine;
5-(2-chloro-phenyl)-pyridin-2-ylamine;
5-(4-methanesulfonyl-phenyl)-pyridin-2-ylamine;
10 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(3-fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2,3-dichloro-phenyl)-pyridin-2-ylamine;
5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine;
5-(2,5-dichloro-phenyl)-pyridin-2-ylamine;
15 5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-ylamine;
5-(2-trifluoromethyl-phenyl)-pyridin-2-ylamine;
5-(2,3-difluoro-phenyl)-pyridin-2-ylamine;
5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine;
5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine;
20 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(5-fluoro-2-methyl-phenyl)-pyridin-2-ylamine;
5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine;
5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-ylamine;
5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine;
25 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine;
30 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-ylamine;
2-Methyl-[3,3']bipyridinyl-6-ylamine;
5-(2-Chloro-phenyl)-4-methyl-pyridin-2-ylamine and
5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-ylamine.

- 28 -

The compounds of formula I described above for use as therapeutically active substance are a further object of the invention.

Also an object of the present invention are compounds as described above for the preparation of medicaments for the prophylaxis and therapy of illnesses which are caused
5 by disorders associated with the enzyme 11 β -hydroxysteroid dehydrogenase1 (11 β HSD1).

Likewise an object of the invention are pharmaceutical compositions comprising a compound of the formula I as described above and a therapeutically inert carrier.

A further preferred embodiment of the present invention is the use of a compound
10 of the formula I as described above for the preparation of medicaments for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension.

Particularly preferred is the use of a compound according to formula I as described above for the preparation of medicaments for the treatment and prophylaxis of diabetes Type II.

15 A further object of the present invention comprises a compound according to formula I as described above, when manufactured according to any one of the described processes.

Also an object of the invention is a method for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension, which method
20 comprises administering an effective amount of a compound of formula I as described above.

Particularly preferred is a method for the treatment and prophylaxis of diabetes Type II, which method comprises administering an effective amount of a compound according to formula I as described above.

25

Assay Procedures

Transient expression and partial Purification:

The cDNA encoding the human 11beta-HSD1 protein was cloned into the expression vector pcDNA3 (Stratagene). This construct (for details see Alex Odermatt et al.; J Biol Chem.,1999, Vol. 274, Issue 40, 28762-28770) was used to transiently express the protein in HEK293 cells (ATCC number: CRL-1573, described in Graham, F.L., Smiley, J., Russell, W.C., Nairn, R.; (1977)) using lipofectamine. 48h after transfection cells were washed twice with ice-cold PBS (Phosphate buffered Saline). To 1 volume of cell suspension in PBS 2 volumes of ice-cold lysis buffer (50mM Tris; pH7.5; 1mM EDTA; 100mM NaCl) were added. The cells were lysed by Potter-homogenization (20 strokes). The resulting homogenate was sonicated with a tip sonicator (10% output; 2 x 30 sec.) and cleared by a low speed centrifugation (10min x 9000g; 4°C). The microsomal fraction was collected by a high speed centrifugation (60 min x 110'000g). The resulting pellet was resuspended in storage buffer (20mM Tris pH 7.5; 1 mM EDTA; 10% Glycerol) and the centrifugation was repeated. The resulting pellet containing the microsomal fraction was again taken up into storage buffer and aliquots were kept frozen in liquid Nitrogen until use.

15

Generation of stable cell lines expressing 11beta-HSD1:

The same construct used for transient expression of human 11beta-HSD1 was also used to establish cell lines stably expressing the protein. Briefly, (HEK293) cells were transfected with 11beta-HSD1 construct using the lipofectamine reagent (Gibco BRL) according to the manufacturer's instruction. Two days after transfection, geneticin selection (0.8 mg/ml) was initiated and several stable clones were isolated. One clone was further used for pharmacological characterization.

Microsome Assay

Microsomes isolated from HEK293 cells transiently expressing human 11beta-HSD1 (for details see above) were incubated in assay buffer (100 mM NaCl; 1mM EDTA; 1mM EGTA; 1mM MgCl; 250 mM Sucrose; 20 mM Tris pH 7.4; Cortisone 50-200nM and NADPH 1mM) together with different concentrations of test substances. After 60 min. of incubation at 37°C the assay was stopped by heating to 80°C (5 min.) and by addition of the inhibitor Carbenoxolone (1 uM). The amount of Cortisol produced in this assay was determined using a commercially available, ELISA-based Cortisol-detection kit

(Distributed by Assay Design, Inc.). Inhibitors were characterized by their IC₅₀ values, e.g. the concentration at which the production of cortisol was 50% reduced.

In this test preferred compounds as described above have IC₅₀ values below 1000 nM; more preferred compounds have IC₅₀ values below 100 nM. Most preferred compounds
5 have IC₅₀ values below 10nM.

Cellular Assay

To measure the effect of inhibitors in intact cells HEK293 cells stably expressing human 11beta-HSD1 (see above) were cultivated in 96 well plates in DMEM. First inhibitors and
10 60 min later Cortisone was added to the cells. After 60 min of incubation at 37°C in a 5% CO₂ atmosphere part of the medium was removed and the conversion from Cortisone to Cortisol was measured using a commercially available ELISA kit (Distributed by Assay Design, Inc.).

15 Results obtained in the microsome assay using representative compounds of the invention as the test compounds are shown in the following table:

<u>Compound</u>	<i>h</i> 11-beta-HSD 1 IC ₅₀ (nM)
Example 2	3
Example 110	12

Compounds as described above have IC₅₀ values below 1000 nM; preferred
20 compounds have IC₅₀ values below 100 nM. More preferred compounds have IC₅₀ values below 10 nM. These results have been obtained by using the foregoing test.

The compounds of formula I and their pharmaceutically acceptable salts and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).

The compounds of formula I and their pharmaceutically acceptable salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.

Suitable adjuvants for soft gelatin capsules, are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.

Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.

Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.

Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.

Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

In accordance with the invention the compounds of formula I and their pharmaceutically acceptable salts can be used for the prophylaxis and treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. The dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into

preferably 1-3 individual doses, which can consist, for example, of the same amounts, should be appropriate. It will, however, be clear that the upper limit given above can be exceeded when this is shown to be indicated.

The invention is illustrated hereinafter by Examples, which have no limiting
5 character.

Examples

10

Example 1

a) A solution of 0.2 g (0.98 mmol) of 5-(2-chloro-phenyl)-pyridin-2-ylamine and 0.23 g of 5-fluoro-2-methyl-benzenesulfonyl chloride (1.1 mmol) in pyridine (10 ml) was stirred at RT until completion of reaction according to HPLC analysis (48 h). After concentration in vacuo the residue was taken up in EtOAc, the solution washed with 1 N aqueous HCl,
15 saturated brine then dried over sodium sulphate and concentrated in vacuo. The precipitate was collected by filtration and dried in a high vacuum to give 0.21 g (57%) of N-[5-(2-chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as an off-white crystalline solid. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

20

Preparation of the starting material:

b) A suspension of 70 mg (0.06 mmol) of tetrakis(triphenylphosphine) palladium(0) in benzene (4 ml) was treated at RT under an argon atmosphere successively with 0.35 g (2 mmol) of 2-amino-5-bromo-pyridine, 2.2 ml (4.4 mmol) of 2 M aqueous Na_2CO_3
25 solution, 0.34 g (2.2 mmol) of 2-chlorophenylboronic acid in ethanol (1 ml) and heated to reflux for 24 h. The reaction mixture was cooled and partitioned between EtOAc and water. The layers were separated, the organic layer dried over sodium sulphate and concentrated in vacuo. The residue was applied to a silica gel column with EtOAc as eluent. Combination of the purified fractions and concentration in vacuo gave 0.4 g (98%)

- 33 -

of the desired 5-(2-chloro-phenyl)-pyridin-2-ylamine as white crystalline solid. ISP mass spectrum, m/e: 205.1 (M+1 calculated for $C_{11}H_9ClN_2$: 205).

Example 2

- 5 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 391 (M-1 calculated for $C_{18}H_{14}Cl_2N_2O_2S$: 391).

10

Example 3

- a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

15

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 2-amino-5-bromo-pyridine with 2,4-dichlorophenylboronic acid there was obtained: 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine as a white crystalline solid which was used without further purification in the
20 subsequent reaction step.

Example 4a

- In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an off-white solid. ISN
25 mass spectrum, m/e: 425 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

Example 4b

- 34 -

a) In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

5

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2-chlorophenylboronic acid there was obtained: 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine as a white crystalline solid. ISP mass spectrum, m/e: 219.2 (M+1 calculated for C_{12}

10 $H_{11}ClN_2$: 219).

Example 5

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with biphenyl-4-sulfonyl chloride there was obtained: Biphenyl-4-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide as a white foam. ISN mass spectrum, m/e: 433.2 (M-1 calculated for $C_{24}H_{19}ClN_2O_2S$: 433).

15

Example 6

a) In analogy to example 1, on reaction of 5-(2-chloro-4-fluoro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

20

25 Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 2-chloro-4-fluoro-phenylboronic acid there was obtained: 5-(2-chloro-4-fluoro-phenyl)-pyridin-2-ylamine as a white crystalline solid which was used without further purification in the next reaction step.

30

Example 7

- a) In analogy to example 1, on reaction of 5-(3-fluoro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(3-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass
5 spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 3-fluorophenylboronic acid there was obtained: 5-(3-fluoro-phenyl)-pyridin-2-ylamine as a white
10 crystalline solid which was used without further purification in the next reaction step.

Example 8

- a) In analogy to example 1, on reaction of 5-(2,4-difluoro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid.
15 ISN mass spectrum, m/e: 392.9 (M-1 calculated for $C_{18}H_{13}ClF_2N_2O_2S$: 392).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 2,4-difluorophenylboronic acid there was obtained: 5-(2,4-difluoro-phenyl)-pyridin-2-ylamine as a white crystalline which was used without further purification in the next
20 reaction step.

Example 9

- 25 In analogy to example 1, on reaction of 5-(2,4-difluoro-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 377.1 (M-1 calculated for $C_{18}H_{13}F_3N_2O_2S$: 377).

- 36 -

Example 10

- a) In analogy to example 1, on reaction of 5-(4-methoxy-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid.
- 5 ISN mass spectrum, m/e: 387.1 (M-1 calculated for $C_{19}H_{17}ClN_2O_2S$: 387).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 4-methoxy-phenylboronic acid there was obtained: 5-(4-methoxy-phenyl)-pyridin-2-ylamine as a
- 10 beige crystalline solid which was used without further purification in the next reaction step.

Example 11

- a) In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass
- 15 spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 4-fluoro-phenylboronic acid there was obtained: 5-(4-fluoro-phenyl)-pyridin-2-ylamine as a brown
- 20 crystalline solid which was used without further purification in the next reaction step.

Example 12

- 25 In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline off-white solid. ISN mass spectrum, m/e: 359 (M-1 calculated for $C_{18}H_{14}F_2N_2O_2S$: 359).

30

Example 13

- 37 -

a) In analogy to example 1, on reaction of 5-(2-methoxy-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(2-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 371.1 (M-1 calculated for $C_{19}H_{17}FN_2O_3S$: 371).

5

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 2-methoxy-phenylboronic acid there was obtained: 5-(2-methoxy-phenyl)-pyridin-2-ylamine as yellow oil which was used without further purification in the next reaction step.

10

Example 14

a) In analogy to example 1, on reaction of 5-(2-fluoro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

15

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 2-fluoro-phenylboronic acid there was obtained: 5-(2-fluoro-phenyl)-pyridin-2-ylamine as yellow oil which was used without further purification in the next reaction step.

20

Example 15

In analogy to example 1, on reaction of 5-(2-fluoro-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as amorphous white solid. ISN mass spectrum, m/e: 359 (M-1 calculated for $C_{18}H_{14}F_2N_2O_2S$: 359).

25

Example 16

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a colourless crystalline solid. ISP mass spectrum, m/e: 425 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

5

Example 17

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,5-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 379 (M-1 calculated for $C_{17}H_{11}ClF_2N_2O_2S$: 379).

10

Example 18

a) In analogy to example 1, on reaction of 5-(4-methanesulfonyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-methanesulfonyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 435.1 (M-1 calculated for $C_{19}H_{17}ClN_2O_4S_2$: 435).

15

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-pyridin-2-ylamine with 4-methanesulfonyl-phenylboronic acid there was obtained: 5-(4-methanesulfonyl-phenyl)-pyridin-2-ylamine as a white crystalline solid which was used without further purification in the next reaction step.

20

Example 19

a) In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a yellow foam. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

25

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 4-fluoro-phenylboronic acid there was obtained: 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine as a yellow crystalline solid which was used without further purification in the next reaction step.

Example 20

- In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 373.1 (M-1 calculated for $C_{19}H_{16}F_2N_2O_2S$: 373).

Example 21

- a) In analogy to example 1, on reaction of 5-(3-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a yellow foam. ISN mass spectrum, m/e: 389.1 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 3-fluoro-phenylboronic acid there was obtained: 5-(3-fluoro-phenyl)-6-methyl-pyridin-2-ylamine as a white crystalline solid which was used without further purification in the next reaction step.

Example 22

- In analogy to example 1, on reaction of 5-(3-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 373.1 (M-1 calculated for $C_{19}H_{16}F_2N_2O_2S$: 373).

- 40 -

Example 23

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3,4-dimethoxy-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide as a light-yellow foam. ISN
5 mass spectrum, m/e: 437.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_4S$: 437).

Example 24

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3,4-dichloro-benzenesulfonyl chloride there was obtained: 3,4-Dichloro-N-[5-(2,4-
10 dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide as an crystalline white solid. ISN mass spectrum, m/e: 446.9 (M-1 calculated for $C_{17}H_{10}Cl_4N_2O_2S$: 447).

Example 25

a) In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with
15 2,5-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide as a light-red solid. ISN mass spectrum, m/e: 413 (M-1 calculated for $C_{17}H_{10}Cl_2F_2N_2O_2S$: 413).

Preparation of the starting material:

20 b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 2,3-dichloro-phenylboronic acid there was obtained: 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine as an of-white crystalline solid. EI mass spectrum, m/e: 239.1 (M calculated for $C_{11}H_8Cl_2N_2$: 239).

25

Example 26

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass
spectrum, m/e: 427 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 427).

30

Example 27

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3,4-dichloro-benzenesulfonyl chloride there was obtained: 3,4-dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 411 (M-1 calculated for $C_{17}H_{11}Cl_3N_2O_2S$: 411).

Example 28

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3,4-dimethoxy-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 403.2 (M-1 calculated for $C_{19}H_{17}ClN_2O_4S$: 403).

Example 29

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 391 (M+1 calculated for $C_{18}H_{14}Cl_2N_2O_4S$: 391).

Example 30

a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 373 (M-1 calculated for $C_{19}H_{16}F_2N_2O_2S$: 373).

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 4-fluoro-2-methyl-phenylboronic acid there was obtained: 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-

ylamine as a white solid. ISP mass spectrum, m/e: 203.1 (M+1 calculated for $C_{12}H_{11}FN_2$: 203).

Example 31

5 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 389.1 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Example 32

10

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3-chloro-4-methoxy-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide as a white solid. ISP mass spectrum, m/e: 409.2 (M+1 calculated for $C_{18}H_{14}Cl_2N_2O_3S$: 409).

15

Example 33

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 4,5-dichloro-2-fluoro-benzenesulfonyl chloride there was obtained: 4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide as a white solid. ISP mass spectrum, m/e: 431.2 (M+1 calculated for $C_{17}H_{10}Cl_3FN_2O_3S$: 431).

20

Example 34

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-4-methoxy-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide as an crystalline white solid. ISP mass spectrum, m/e: 443.1 (M+1 calculated for $C_{18}H_{13}Cl_3N_2O_3S$: 443).

25

Example 35

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide as a crystalline white solid. ISP mass spectrum, m/e: 427.2 (M+1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 427).

5

Example 36

A solution of 0.23 g (1 mmol) of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine and 0.2 g (1.1 mmol) of piperidine-1-sulfonyl chloride (preparation: Bull.Soc.Chim.Fr.; 1936, p2143) in pyridine (10 ml) was heated to reflux until completion of reaction according to HPLC analysis (20 h). After concentration in vacuo the residue was taken up in EtOAc, which was then washed with 1N aqueous HCl, saturated brine, dried over sodium sulphate and concentrated in vacuo. The residue was applied to a silica gel column with EtOAc/toluene (9/1 to 1/1) as eluent. Combination of the purified fractions and concentration in vacuo gave 0.26 g (67%) of the desired piperidine-1-sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide as a brown crystalline solid. ISN mass spectrum, m/e: 384 (M-1 calculated for $C_{16}H_{17}Cl_2N_2O_2S$: 384).

15

Example 37

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 2-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-2-trifluoromethyl-benzenesulfonamide as a light-red solid. ISN mass spectrum, m/e: 445 (M-1 calculated for $C_{18}H_{11}Cl_2F_3N_2O_2S$: 445).

20

25

Example 38

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 395 (M-1 calculated for $C_{17}H_{11}Cl_2FN_2O_2S$: 395).

30

Example 39

- a) In analogy to example 1, on reaction of 5-(2,5-dichloro-phenyl)-pyridin-2-ylamine with 2,5-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide as a light yellow amorphous solid. ISN
5 mass spectrum, m/e: 413 (M-1 calculated for $C_{17}H_{10}Cl_2F_2N_2O_2S$: 413).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 2,3-dichloro-phenylboronic acid there was obtained: 5-(2,5-dichloro-phenyl)-pyridin-2-ylamine as an off-white crystalline solid. EI mass spectrum, m/e: 239.1 (M calculated for $C_{11}H_8Cl_2N_2$: 239).
10

Example 40

- In analogy to example 1, on reaction of 5-(2,5-dichloro-phenyl)-pyridin-2-ylamine with
15 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

Example 41

- 20 In analogy to example 1, on reaction of 5-(2,5-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,5-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 427.1 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 427).

25

Example 42

- a) In analogy to example 1, on reaction of 5-(2-fluoro-5-trifluoromethyl -phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid solid. ISN mass spectrum, m/e: 427.2 (M-1 calculated for $C_{19}H_{13}F_5N_2O_2S$:
30 427).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 2-fluoro-5-trifluoromethyl-phenylboronic acid there was obtained: 5-(2-fluoro-5-trifluoromethyl -phenyl)-pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 257 (M+H calculated for $C_{12}H_8F_4N_2$: 257).

Example 43

- In analogy to example 1, on reaction of 5-(2-fluoro-5-trifluoromethyl -phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid ISN mass spectrum, m/e: 442.9 (M-1 calculated for $C_{19}H_{13}ClF_4N_2O_2S$: 443).

Example 44

- a) In analogy to example 1, on reaction of 5-(2-trifluoromethyl -phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-2-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as an orange solid. ISN mass spectrum, m/e: 425 (M-1 calculated for $C_{19}H_{14}ClF_3N_2O_2S$: 425).

- Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 2-trifluoromethyl-phenylboronic acid there was obtained: 5-(2-trifluoromethyl-phenyl)-pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 239.2 (M+H calculated for $C_{12}H_9F_3N_2$: 239).

25

Example 45

- In analogy to example 1, on reaction of 5-(2-trifluoromethyl -phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-4-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as a light-grey solid. ISP mass spectrum, m/e: 425 (M-1 calculated for $C_{19}H_{14}ClF_3N_2O_2S$: 425).

30

Example 46

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 5-chloro-2-methoxy-benzenesulfonyl chloride there was obtained: 5-chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methoxy-benzenesulfonamide as a crystalline white solid. ISP mass spectrum, m/e: 443.1 (M+1 calculated for $C_{18}H_{13}Cl_3N_2O_3S$: 443).

Example 47

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-acetylamino-3-chloro-benzenesulfonyl chloride there was obtained: N-{2-Chloro-4-[5-(2,4-dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenyl}-acetamide as a crystalline brown solid. ISN mass spectrum, m/e: 468 (M-1 calculated for $C_{19}H_{14}Cl_3N_3O_3S$: 468).

Example 48

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 445 (M-1 calculated for $C_{18}H_{11}Cl_2F_3N_2O_2S$: 445)

Example 49

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-methylsulfonyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-methylsulfonyl-benzenesulfonamide as a crystalline light-brown solid. ISN mass spectrum, m/e: 455.1 (M-1 calculated for $C_{18}H_{14}Cl_2N_2O_4S_2$: 455).

Example 50

a) In analogy to example 1, on reaction of 5-(2,3-difluoro-phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3-

5 difluoro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 392.9 (M-1 calculated for $C_{18}H_{13}ClF_2N_2O_2S$: 393).

Preparation of the starting material:

- 5 b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 2,3-difluoro-phenylboronic acid there was obtained: 5-(2,3-difluoromethyl-phenyl)-pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 207.2 (M+H calculated for $C_{11}H_8F_2N_2$: 207).

10

Example 51

In analogy to example 1, on reaction of 5-(2,3-difluoro-phenyl)-pyridin-2-ylamine with 3-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: x377.2 (M-1 calculated for $C_{18}H_{13}F_3N_2O_2S$: 377).

15

Example 52

- a) In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-2-methyl-benzenesulfonamide as a
20 white solid. ISN mass spectrum, m/e: 493 (M-1 calculated for $C_{20}H_{13}ClF_6N_2O_2S$: 493).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 2,4-bis-trifluoromethyl-phenylboronic acid there was obtained: 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 307.2 (M+1
25 calculated for $C_{13}H_8F_6N_2$: 307).

Example 53

- 48 -

a) In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 493 (M-1 calculated for $C_{20}H_{13}ClF_6N_2O_2S$: 493).

5

Example 54

In analogy to example 1, on reaction of 5-(2,3-difluoro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 392 (M-1 calculated for $C_{18}H_{13}ClF_2N_2O_2S$: 392).

10

Example 55

In analogy to example XX, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with piperidine-1-sulfonyl chloride there was obtained: Piperidine-1-sulfonic acid [5-(2,3-dichloro-phenyl)-pyridin-2-yl]-amide as an off-white solid. ISN mass spectrum, m/e: 384 (M-1 calculated for $C_{16}H_{17}Cl_2N_3O_2S$: 384).

15

Example 56

In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 5-chloro-2-methoxy-benzenesulfonyl chloride there was obtained: 5-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methoxy-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 405.2 (M-1 calculated for $C_{19}H_{16}ClFN_2O_3S$: 405).

20

Example 57

In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-acetylaminobenzene-3-chloro-benzenesulfonyl chloride there was obtained: N-{2-Chloro-4-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylsulfamoyl]-phenyl}-acetamide as a light-brown solid. ISN mass spectrum, m/e: 432.2 (M-1 calculated for $C_{20}H_{17}ClFN_3O_3S$: 432).

25

30

- 49 -

Example 58

In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a brown foam.

5 ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{19}H_{14}F_4N_2O_2S$: 409).

Example 59

In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-methanesulfonyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methanesulfonyl-benzenesulfonamide as a brown
10 viscous oil. ISN mass spectrum, m/e: 419 (M-1 calculated for $C_{19}H_{17}FN_2O_4S_2$: 419).

Example 60

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with
15 (4-chlorosulfonyl-phenoxy)-acetic acid methyl ester there was obtained: {4-[5-(2,3-dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl ester as a white solid. ISN mass spectrum, m/e: 465 (M-1 calculated for $C_{20}H_{16}Cl_2N_2O_5S$: 465).

Example 61

20 In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-trifluoromethoxy-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluorophenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide as a light-brown foam. ISP mass spectrum, m/e: 427.3 (M+1 calculated for $C_{19}H_{14}F_4N_2O_3S$: 427).

25

Example 62

In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-methoxy-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methoxy-benzenesulfonamide as a light-brown foam. ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}ClFN_2O_3S$: 405).

Example 63

In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as a light-brown foam. ISN mass spectrum, m/e: 403.1 (M-1 calculated for $C_{20}H_{18}ClFN_2O_2S$: 403).

Example 64

A solution of 120 mg (2.6 mmol) of 4-[5-(2,3-Dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl ester, product of example 60, in THF/EtOH (each 5 ml) was treated with 57 mg (5.1 mmol) of $CaCl_2$, cooled to 0° C and then 39 mg (1 mmol) of sodium borohydride were added portionwise. The mixture was stirred for 12 h at RT, poured into ice/water acidified with 3 M HCl to pH 1 and extracted with AcOEt. The layers were separated, the organic layer dried over sodium sulphate and concentrated in vacuo. The residue was applied to a silica gel column with EtOAc/heptan (1/1) then CH_2Cl_2 /MeOH (95/5) as eluent. Combination of the purified fractions and concentration in vacuo gave 0.1 g (93%) of the desired N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-(2-hydroxy-ethoxy)-benzenesulfonamide as white foam. ISN mass spectrum, m/e: 437.2 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_4S$: 437).

20

Example 65

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

25

Example 66

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-

- 51 -

chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white foam.
ISN mass spectrum, m/e: 405.2 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

Example 67

- 5 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 391 (M-1 calculated for $C_{18}H_{14}Cl_2N_2O_2S$: 391).

10

Example 68

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4,6-dichloro-2-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 439 (M-1 calculated for $C_{19}H_{15}Cl_3N_2O_2S$: 439).

15

Example 69

- In analogy to example 36, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4 piperidine-1-sulfonyl chloride there was obtained: Piperidine-1-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide as a white foam. ISN mass spectrum, m/e:
20 364 (M-1 calculated for $C_{17}H_{20}ClN_3O_2S$: 364).

Example 70

- In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin-
25 2-yl]-4-fluoro-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 394.9 (M-1 calculated for $C_{17}H_{11}Cl_2FN_2O_2S$: 395).

Example 71

- 52 -

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 439 (M-1 calculated for $C_{19}H_{15}Cl_3N_2O_2S$: 439).

5

Example 72

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 2,4-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide as a crystalline white solid. ISN mass
10 spectrum, m/e: 413.1 (M-1 calculated for $C_{17}H_{10}Cl_2F_2N_2O_2S$: 413).

Example 73

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-
15 (2,4-dichloro-phenyl)-pyridin-2-yl]-5-methyl-benzenesulfonamide as a amorphous white solid. ISN mass spectrum, m/e: 459 (M-1 calculated for $C_{18}H_{12}Cl_4F_2N_2O_2S$: 459).

Example 74

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3-
20 trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 445 (M-1 calculated for $C_{18}H_{11}Cl_2F_3N_2O_2S$: 445).

Example 75

25 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 373.1 (M-1 calculated for $C_{19}H_{16}F_2N_2O_2S$: 373).

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 4-fluoro-2-methyl-phenylboronic acid there was obtained: 5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine as a yellow solid which was used directly in the next reaction step.

Example 76

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 403.2 (M-1 calculated for $C_{20}H_{18}ClFN_2O_2S$: 403).

Example 77

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 387.1 (M-1 calculated for $C_{20}H_{18}F_2N_2O_2S$: 387).

Example 78

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 425 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

Example 79

- 54 -

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 4-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 444.9 (M-1 calculated for $C_{18}H_{11}Cl_2F_3N_2O_2S$: 445).

5

Example 80

a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white
10 solid. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Example 81

a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(4-
15 Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{19}H_{14}F_4N_2O_2S$: 409).

Example 82

a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 4-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(4-
20 Fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{19}H_{14}F_4N_2O_2S$: 409).

Example 83

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-
25 pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 411 (M-1 calculated for $C_{18}H_{12}ClF_3N_2O_3S$: 411).

- 55 -

Example 84

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 4-ethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-ethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 371.1 (M-1
5 calculated for $C_{19}H_{17}ClN_2O_2S$: 371).

Example 85

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-
10 pyridin-2-yl]-benzenesulfonamide as white crystals. ISN mass spectrum, m/e: 377.1 (M-1 calculated for $C_{17}H_{12}Cl_2N_2O_3S$: 377).

Example 86

In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-
15 chloro-4-fluoro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 429.1 (M-1 calculated for $C_{17}H_{10}Cl_3FN_2O_2S$: 429).

Example 87

20 In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-ethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-ethyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

25

Example 88

a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-

- 56 -

phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white foam. ISP mass spectrum, m/e: 444.9 (M-1 calculated for $C_{18}H_{11}Cl_2F_3N_2O_2S$: 445).

Example 89

- 5 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 425 (M-1 calculated for $C_{19}H_{14}ClF_3N_2O_2S$: 425).

10

Example 90

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-trifluoromethoxy-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 441.1 (M-1 calculated for $C_{19}H_{14}ClF_3N_2O_3S$: 441).

15

Example 91

- In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 361 (M-1
20 calculated for $C_{17}H_{12}ClFN_2O_2S$: 361).

Example 92

- In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,4-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2-
25 yl]-2,4-difluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 379 (M-1 calculated for $C_{17}H_{11}ClF_2N_2O_2S$: 379).

Example 93

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

5

Example 94

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 419 (M-1 calculated for $C_{20}H_{18}Cl_2N_2O_2S$: 419).

10

Example 95

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 392.9 (M+1 calculated for $C_{18}H_{13}ClF_2N_2O_2S$: 393).

15

Example 96

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3,5-dichloro-benzenesulfonyl chloride there was obtained: 3,5-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 425 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

20

Example 97

a) In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a colourless waxy solid. ISN mass spectrum, m/e: 459 (M-1 calculated for $C_{19}H_{13}Cl_2F_3N_2O_2S$: 459).

30

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 2,4-dichloro-phenylboronic acid there was obtained: of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine as a brown crystalline solid. ISP mass spectrum, m/e: 253 (M+1
5 calculated for $C_{12}H_{10}Cl_2N_2$: 253).

Example 98

- In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as an colorless waxy solid.
10 ISn mass spectrum, m/e: 409 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

Example 99

- In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide as a colorless
15 foam. ISN mass spectrum, m/e: 427.1 (M-1 calculated for $C_{18}H_{12}Cl_2F_2N_2O_2S$: 427).

Example 100

- 20 In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as a white powder. ISN mass spectrum, m/e: 453.1 (M-1 calculated for $C_{20}H_{17}Cl_3N_2O_2S$: 453).

25

Example 101

- a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white foam. ISN
30 mass spectrum, m/e: 458.9 (M-1 calculated for $C_{18}H_{12}Cl_4N_2O_2S$: 458).

Example 102

- a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 411 (M-1 calculated for $C_{17}H_{11}Cl_3N_2O_2S$: 411).

Example 103

- a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide as an off-white foam. ISP mass spectrum, m/e: 411 (M-1 calculated for $C_{17}H_{11}Cl_3N_2O_2S$: 411).

Example 104

- In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

Example 105

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 391 (M-1 calculated for $C_{18}H_{14}Cl_2N_2O_2S$: 391).

Example 106

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-

- 60 -

chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 424.9 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

Example 107

- 5 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 439 (M-1 calculated for $C_{19}H_{15}Cl_3N_2O_2S$: 439).

10

Example 108

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 423 (M-1 calculated for $C_{20}H_{16}F_4N_2O_2S$: 423).

15

Example 109

- In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 437.2 (M-1 calculated for $C_{20}H_{17}Cl_2FN_2O_2S$: 437).

20

Example 110

- 25 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

- 61 -

Example 111

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow
5 foam. ISN mass spectrum, m/e: 389.1 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Example 112

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-trifluoromethoxy-benzenesulfonyl chloride there was obtained: N-[5-(4-
10 Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 439.1 (M-1 calculated for $C_{20}H_{16}F_4N_2O_3S$: 439).

Example 113

15 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 369 (M-1 calculated for $C_{20}H_{19}FN_2O_2S$: 369).

20

Example 114

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 2-chloro-5-trifluoromethyl-benzenesulfonyl chloride there was obtained: 2-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 457.1 (M-1
25 calculated for $C_{20}H_{15}ClF_4N_2O_2S$: 457).

Example 115

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained:

2-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 441.1 (M-1 calculated for $C_{20}H_{15}F_5N_2O_2S$: 441).

5

Example 116

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 371.2 (M-1 calculated for $C_{19}H_{17}ClN_2O_2S$: 371).

10

Example 117

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-fluoro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a light-yellow
15 viscous oil. ISN mass spectrum, m/e: 409.3 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

Example 118

In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-5-trifluoromethyl-benzenesulfonyl chloride there was obtained: 2-Chloro-
20 N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 459.2 (M-1 calculated for $C_{19}H_{13}Cl_2F_3N_2O_2S$: 459).

Example 119

25 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 442.9 (M-1 calculated for $C_{19}H_{13}ClF_4N_2O_2S$: 443).

Example 120

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3-fluoro-4-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-fluoro-4-methyl-benzenesulfonamide as a colorless solid. ISN mass spectrum, m/e: 409.1 (M-1 calculated for $C_{18}H_{13}Cl_2N_2O_2S$: 409).

Example 121

In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3,5-dimethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3,5-dimethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

Example 122

a) In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409.1 (M-1 calculated for $C_{19}H_{14}F_4N_2O_2S$: 409).

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 5-fluoro-2-methyl-phenylboronic acid there was obtained: 5-(5-fluoro-2-methyl-phenyl)-pyridin-2-ylamine as a light yellow oil. ISP mass spectrum, m/e: 203.1 (M+1 calculated for $C_{12}H_{11}FN_2$: 203).

Example 123

a) In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 359 (M-1 calculated for $C_{18}H_{14}F_2N_2O_2S$: 359).

- 64 -

Example 124

a) In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389.1 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Example 125

a) In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 425.1 (M-1 calculated for $C_{19}H_{14}ClF_3N_2O_2S$: 425).

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 5-chloro-2-methyl-phenylboronic acid there was obtained: 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine as a white solid. EI mass spectrum, m/e: 218.1 (M calculated for $C_{12}H_{11}ClN_2$: 218).

20

Example 126

In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

25

Example 127

In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(5-

- 65 -

chloro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid.

ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

Example 128

- 5 a) In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(6-chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 422.9 (M-1 calculated for $C_{19}H_{15}Cl_2FN_2O_2S$: 423).

10

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo -pyridin-2-ylamine with 6-Chloro-2-fluoro-3-methyl-phenylboronic acid there was obtained: 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine as a white solid. EI mass spectrum, m/e: 237.1 (M calculated for $C_{12}H_{10}ClFN_2$: 237).

15

Example 129

In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 443.2 (M-1 calculated for $C_{19}H_{13}ClF_4N_2O_2S$: 443).

20

Example 130

- 25 In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 393.1 (M-1 calculated for $C_{18}H_{13}ClF_2N_2O_2S$: 393).

- 66 -

Example 131

- a) In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an orange oil. ISN mass spectrum, m/e: 439 (M-1 calculated for $C_{20}H_{16}ClF_3N_2O_2S$: 439).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 5-chloro-2-methyl-phenylboronic acid there was obtained: 5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 233 (M+1 calculated for $C_{13}H_{13}ClN_2$: 233).

Example 132

- a) In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

20

Example 133

- a) In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 419 (M-1 calculated for $C_{20}H_{18}Cl_2N_2O_2S$: 419).

25

Example 134

- a) In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-

30

- 67 -

trifluoromethyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 457.2 (M-1 calculated for $C_{20}H_{15}ClF_4N_2O_2S$: 457).

Preparation of the starting material

- 5 b) In analogy to example 1b), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 6-Chloro-2-fluoro-3-methyl-phenylboronic acid there was obtained: 5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine as which was used without further purification in the next reaction step.

10

Example 135

In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 407.2 (M-1 calculated for $C_{19}H_{15}ClFN_2O_2S$: 407).

15

Example 136

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

20

25

Example 137

In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

Example 138

- a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 422.9 (M-1 calculated for $C_{19}H_{15}Cl_2FN_2O_2S$: 423).

Example 139

- 10 a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 425 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

- 15 Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 2,5-dichloro-phenylboronic acid there was obtained: 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine as white solid. EI mass spectrum, m/e: 252.1 (M calculated for $C_{12}H_{10}Cl_2N_2$: 252).

20

Example 140

- a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

Example 141

- a) In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(5-

- 69 -

Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 422.9 (M-1 calculated for $C_{20}H_{16}F_4N_2O_2S$: 423).

5 Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-phenylboronic acid there was obtained: 5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine a light-yellow oil. EI mass spectrum, m/e: 216.2 (M calculated for $C_{13}H_{13}FN_2$: 216).

10

Example 142

a) In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off-
15 white solid. ISN mass spectrum, m/e: 373.1 (M-1 calculated for $C_{19}H_{16}F_2N_2O_2S$: 373).

Example 143

a) In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-
20 N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Example 144

a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an
25 orange oil. ISN mass spectrum, m/e: 459 (M-1 calculated for $C_{19}H_{13}Cl_2F_3N_2O_2S$: 459).

Example 145

- 70 -

- a) In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 442.9 (M-1 calculated for $C_{19}H_{13}ClF_4N_2O_2S$: 443).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2-chloro-4-fluoro-phenylboronic acid there was obtained: 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine as an off-white solid. EI mass spectrum, m/e: 236.1 (M calculated for $C_{12}H_{10}ClFN_2$: 236).

Example 146

- In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 392.9 (M-1 calculated for $C_{18}H_{13}ClF_2N_2O_2S$: 393).

Example 147

In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

Example 148

- a) In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a

- 71 -

light-yellow amorphous solid. ISN mass spectrum, m/e: 459.2 (M-1 calculated for $C_{19}H_{13}Cl_2F_3N_2O_2S$: 459).

Preparation of the starting material:

- 5 b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2,3-dichloro -phenylboronic acid there was obtained: 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine an off-white solid. EI mass spectrum, m/e: 252.1 (M calculated for $C_{12}H_{10}Cl_2N_2$: 252).

10

Example 149

a) In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409.3 (M-1 calculated for $C_{18}H_{13}Cl_2FN_2O_2S$: 409).

15

Example 150

In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 425.1 (M-1 calculated for $C_{18}H_{13}Cl_3N_2O_2S$: 425).

20

Example 151

In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-
25 Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 473.1 (M-1 calculated for $C_{19}H_{14}Cl_4N_2O_2S$: 473).

Example 152

- 72 -

In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 405.3 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

5

Example 153

a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 475 (M-1 calculated for $C_{19}H_{14}Cl_4F_3N_2O_2S$: 475).

10

Example 154

In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

15

Example 155

In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 457.1 (M-1 calculated for $C_{19}H_{14}Cl_3FN_2O_2S$: 457).

20

Example 156

In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 479 (M-1 calculated for $C_{19}H_{11}ClF_6N_2O_2S$: 479).

30

Example 157

In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 459.1 (M-1 calculated for $C_{20}H_{14}F_6N_2O_2S$: 459).

Example 158

In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 463 (M-1 calculated for $C_{20}H_{11}F_7N_2O_2S$: 463).

Example 159

In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 476.9 (M-1 calculated for $C_{19}H_{12}Cl_2F_4N_2O_2S$: 477).

Example 160

In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-fluoro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 442.9 (M-1 calculated for $C_{18}H_{12}Cl_3FN_2O_2S$: 443).

Example 161

- 74 -

a) In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 375.2 (M-1 calculated for $C_{18}H_{14}ClFN_2O_2S$: 375).

5

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2-fluoro-phenylboronic acid there was obtained: -(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine an off-white solid. EI mass spectrum, m/e: 202.2 (M calculated for $C_{12}H_{11}FN_2$: 202).

10

Example 162

a) In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 359 (M-1 calculated for $C_{18}H_{14}F_2N_2O_2S$: 359).

15

Example 163

a) In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 427.1 (M-1 calculated for $C_{19}H_{13}F_5N_2O_2S$: 427).

20

Example 164

In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine with 3-chloro-4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-fluoro-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 496.9 (M-1 calculated for $C_{19}H_{10}ClF_7N_2O_2S$: 497)

30

- 75 -

Example 165

In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-3-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 422.9 (M-1 calculated for $C_{19}H_{15}Cl_2FN_2O_2S$: 423).

Example 166

In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 409.1 (M-1 calculated for $C_{19}H_{14}F_4N_2O_2S$: 409).

Example 167

a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 439.1 (M-1 calculated for $C_{20}H_{16}ClF_3N_2O_2S$: 439).

20 Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-3,4-dimethyl-pyridin-2-ylamine with 2-chloro-phenylboronic acid there was obtained: 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-ylamine a white solid. ISP mass spectrum, m/e: 233 (M+1 calculated for $C_{13}H_{13}ClN_2$: 233).

25

Example 168

a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 405.1 (M-1 calculated for $C_{19}H_{16}Cl_2N_2O_2S$: 405).

Example 169

In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Example 170

a) In analogy to example 1, on reaction of 2-Methyl-[3,3']bipyridinyl-6-ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-(2-Methyl-[3,3']bipyridinyl-6-yl)-3-trifluoromethyl-benzenesulfonamide as a light-yellow amorphous solid. ISN mass spectrum, m/e: 392 (M-1 calculated for $C_{18}H_{14}F_3N_3O_2S$: 392).

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 3-pyridylboronic acid there was obtained: 2-Methyl-[3,3']bipyridinyl-6-ylamine a yellow solid. EI mass spectrum, m/e: 185.2 (M calculated for $C_{11}H_{11}N_3$: 185).

Example 171

a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 391 (M-1 calculated for $C_{18}H_{14}Cl_2N_2O_2S$: 391).

Preparation of the starting material:

b) In analogy to example 1b), on reaction of 5-bromo-4-methyl-pyridin-2-ylamine with 2-chloro-phenylboronic acid there was obtained: 5-(2-Chloro-phenyl)-4-methyl-pyridin-2-ylamine a yellow solid. EI mass spectrum, m/e: 218.1 (M calculated for $C_{12}H_{11}ClN_2$: 218).

- 77 -

Example 172

- a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 425.1 (M-1 calculated for $C_{19}H_{14}ClF_3N_2O_2S$: 425).

Example 173

- a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 439 (M-1 calculated for $C_{19}H_{15}Cl_3N_2O_2S$: 439).

Example 174

- In analogy to example 1, on reaction of 2-Methyl-[3,3']bipyridinyl-6-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-(2-methyl-[3,3']bipyridinyl-6-yl)-benzenesulfonamide as a light-brown amorphous solid. ISN mass spectrum, m/e: 358 (M-1 calculated for $C_{17}H_{14}ClN_3O_2S$: 358).

Example 175

In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide as a colorless solid. ISN mass spectrum, m/e: 389 (M-1 calculated for $C_{19}H_{16}ClFN_2O_2S$: 389).

Preparation of the starting material:

- b) In analogy to example 1b), on reaction of 5-bromo-4-methyl-pyridin-2-ylamine with 2-chloro-phenylboronic acid there was obtained: 5-(4-Fluoro-2-methyl-phenyl)-4-methyl-

- 78 -

pyridin-2-ylamine as an amorphous light-yellow solid. ISP mass spectrum, m/e: 217.3 (M+1 calculated for $C_{13}H_{13}FN_2$: 217).

Example 176

- 5 a) In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 423 (M-1 calculated for $C_{20}H_{16}F_4N_2O_2S$: 423).

10

Example 177

- a) In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-trifluoromethyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 437.2 (M-1 calculated for $C_{20}H_{17}Cl_2FN_2O_2S$: 437).

15

Example A

- A compound of formula I can be used in a manner known per se as the active
20 ingredient for the production of tablets of the following composition:

	<u>Per tablet</u>
Active ingredient	200 mg
Microcrystalline cellulose	155 mg
Corn starch	25 mg
25 Talc	25 mg
Hydroxypropylmethylcellulose	<u>20 mg</u>
	425 mg

- 79 -

Example B


A compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

	<u>Per capsule</u>
5 Active ingredient	100.0 mg
Corn starch	20.0 mg
Lactose	95.0 mg
Talc	4.5 mg
Magnesium stearate	<u>0.5 mg</u>
10	220.0 mg

- 80 -

CLAIMS

1. Compounds of formula



5 wherein

R^1 is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;

R^2 is hydrogen, alkyl or halogen;

R^3 is hydrogen, alkyl or halogen;

10 R^4 is phenyl, naphthyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, 15 alkoxy carbonylalkoxy and alkyl-SO₂-;

R^5 is hydrogen or alkyl;

R^6 , R^7 , R^8 , R^9 and R^{10} are independently selected from hydrogen, alkyl, halogen, cyano, trifluoromethyl, alkoxy and alkyl-SO₂-;

A is nitrogen or C- R^{10} ;

20 E is nitrogen or C- R^9 ;

- 81 -

G is nitrogen or C-R⁸;

wherein not more than one of A, E and G is nitrogen;

and pharmaceutically acceptable salts and esters thereof.

2. Compounds according to claim 1, wherein R¹ is hydrogen.
- 5 3. Compounds according to claim 1, wherein R¹ is alkyl.
4. Compounds according to any one of claims 1 to 3, wherein R² is hydrogen.
5. Compounds according to any one of claims 1 to 3, wherein R² is alkyl.
6. Compounds according to any one of claims 1 to 5, wherein R³ is hydrogen.
7. Compounds according to any one of claims 1 to 6, wherein R³ is alkyl.
- 10 8. Compounds according to any one of claims 1 to 7, wherein R⁵ is hydrogen.
9. Compounds according to any one of claims 1 to 8, wherein A is C-R¹⁰.
10. Compounds according to any one of claims 1 to 9, wherein E is C-R⁹.
11. Compounds according to any one of claims 1 to 9, wherein E is nitrogen.
12. Compounds according to any one of claims 1 to 11, wherein G is C-R⁸.
- 15 13. Compounds according to any one of claims 1 to 12, wherein R⁴ is phenyl optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO₂-.
- 20 14. Compounds according to claim 13, wherein R⁴ is phenyl substituted with one to three substituents independently selected from alkyl, halogen and trifluoromethyl.
15. Compounds according to any one of claims 1 to 14, wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, alkyl, halogen and trifluoromethyl.

- 82 -

16. Compounds according to any one of claims 1 to 15, wherein R⁶ is halogen, alkyl or trifluoromethyl.
17. Compounds according to claim 16, wherein R⁶ is chloro, methyl or trifluoromethyl.
18. Compounds according to any one of claims 1 to 17 selected from
 - 5 N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-
10 benzenesulfonamide;
Biphenyl-4-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-
benzenesulfonamide;
3-Chloro-N-[5-(3-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
15 3-Chloro-N-[5-(2,4-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
N-[5-(2,4-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(4-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
5-Fluoro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
20 5-Fluoro-N-[5-(2-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
5-Fluoro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;

- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(4-methanesulfonyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 5 5-Fluoro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 10 5-Fluoro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
- 3,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
- 15 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- 5-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 20 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
- 4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide;

- 84 -

- 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
- 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- Piperidine-1-sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide;
- 5 N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-2-trifluoromethyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
- N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2,5-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 10 5-Fluoro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-2-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 15 3-Chloro-4-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 5-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methoxy-benzenesulfonamide;
- 20 N-[2-Chloro-4-[5-(2,4-dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenyl]-acetamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-methylsulfonyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;

- 85 -

- N-[5-(2,3-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
- N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-2-methyl-benzenesulfonamide;
- N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-methyl-benzenesulfonamide;
- 5 3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- Piperidine-1-sulfonic acid [5-(2,3-dichloro-phenyl)-pyridin-2-yl]-amide;
- 5-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methoxy-benzenesulfonamide;
- 10 N-[2-Chloro-4-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylsulfamoyl]-phenyl]-acetamide;
- N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
- N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methanesulfonyl-benzenesulfonamide;
- 15 {4-[5-(2,3-Dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl ester;
- N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide;
- 20 3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
- 4-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-(2-hydroxy-ethoxy)-benzenesulfonamide;
- 25 N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;

- 86 -

- 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 5 Piperidine-1-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 4-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
- 10 N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-5-methyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide
- 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 15 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 5-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 20 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 25

- 87 -

- N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-ethyl-benzenesulfonamide;
- 5 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-ethyl-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-
- 10 benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- 15 4-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
- 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- 3,5-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 20 N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;

- 4-Chloro-N-[5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 5 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 4-Chloro-N[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 10 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-methyl-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 15 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 20 N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- 2-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide;
- 25

- 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- 3-Chloro-N-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-
5 benzenesulfonamide;
- 2-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide;
- 10 N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-fluoro-4-methyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3,5-dimethyl-benzenesulfonamide;
- N-[5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 15 3-Chloro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 20 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(6-chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-
25 benzenesulfonamide;

- 90 -

- N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
- 10 N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
- 15 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 20 N-[5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 3-Chloro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 25 N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;

- N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 5 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 10 3-Chloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-
- 15 benzenesulfonamide;
- N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 20 N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide;
- N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide;
- 25 3-Chloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;

- 92 -

- 3-Chloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-fluoro-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- N-[5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 10 N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 15 N-(2-Methyl-[3,3']bipyridinyl-6-yl)-3-trifluoromethyl-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 20 2,4-Dichloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 3-Chloro-N-(2-methyl-[3,3']bipyridinyl-6-yl)-benzenesulfonamide;
- 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
- 25 N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide; and

2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide.

19. Compounds according to any one of claims 1 to 18 selected from

N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;

5 3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;

3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;

3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;

4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide;

10 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;

Piperidine-1-sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide;

N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;

3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-benzenesulfonamide;

15 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;

2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;

N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;

N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;


20 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;

3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;


3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;

- N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 5 N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
- 10 2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 15 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
- N-[5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 20 N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
- 25 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;

- 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
- 5 N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide;
- 10 N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide;
- 3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
- 15 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
- N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide; and
- 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide.
- 20
20. A process for the preparation of a compound according to any one of claims 1 to 19 comprising the reaction of a compound according to formula



in the presence of a compound according to formula



wherein R^1 to R^7 , A, E and G are defined as in claim 1.

- 5 21. Compounds according to any one of claims 1 to 19 for use as therapeutically active substance.
22. Compounds according to any one of claims 1 to 19 for the preparation of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the enzyme 11beta-hydroxysteroid dehydrogenase1.
- 10 23. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 19 and a therapeutically inert carrier.
24. The use of a compound according to any one of claims 1 to 19 for the preparation of medicaments for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension.
- 15 25. The use of a compound according to any one of claims 1 to 19 for the preparation of medicaments for the treatment and prophylaxis of diabetes Type II.
26. A compound according to any one of claims 1 to 19, when manufactured according to a process of claim 20.